CD44 and breast cancer: For in situ characterization of breast cancer stem cells, we did not use the combination of markers CD44+CD24−/low, [18, 27] since this combination of positive and negative markers, currently used in cytometry, is more difficult to translate into in situ tissue analyses and cell counts.